METTL10 Inhibitors

METTL10 inhibitors encompass a spectrum of chemical compounds that indirectly diminish the functional activity of this enzyme by modulating the availability of its substrates or co-factors, or by interfering with related enzymatic pathways. Since METTL10 is a putative methyltransferase, its activity relies on the presence of SAM, which serves as a universal methyl donor in transmethylation reactions. Compounds that inhibit S-adenosyl-L-homocysteine hydrolase consequently lead to a decrease in SAM levels, thereby limiting the methyltransferase activity of METTL10. Other molecules compete with SAM or act as byproducts in metabolic pathways that influence SAM levels, further restricting the catalytic potential of METTL10. Moreover, certain inhibitors target the broader enzymatic activity of methyltransferases, which could indirectly inhibit METTL10 by altering the cellular methylation landscape or by depleting the overall pool of available methyl groups. The indirect inhibition mechanisms also include the perturbation of DNA methylation patterns, which could affect the expression levels or functionality of a wide range of methyltransferases, including METTL10. DNA methyltransferase inhibitors, for instance, induce hypomethylation of genomic DNA, leading to changes in gene expression that can downregulate the production or alter the stability of various enzymes and substrates in the methylation process. This can result in a reduced availability of SAM or an increased concentration of its competitive inhibitor, S-adenosyl-L-homocysteine (SAH), both of which can negatively impact METTL10 activity. Furthermore, by affecting the methylation status of specific genes, these inhibitors can modulate the expression of proteins that interact with METTL10, either enhancing or suppressing its activity indirectly.